The existence and definition of benign multiple sclerosis (MS) remain controversial, particularly given the discrepancy between clinical presentation and underlying imaging changes. In this study, we ...

Introduction Multiple sclerosis (MS ... on a population of people with chronic low back pain where we found four major phenotypes for pain, fatigue and mood symptoms (constant low, constant high, ...

Current disease-modifying therapies for multiple sclerosis have limited effects on disability accrual unrelated to relapses, which is thought to be partially caused by chronic, nonresolving ...

hsc.mb.ca Pain can be one of the worst symptoms of multiple sclerosis (MS).1 Modifiable factors, including depression and anxiety, may influence its severity and impact.2 Opioids used for chronic non ...

A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis ... progression in clinical trials and routine ...

Since returning to office, President Trump’s campaign to exact revenge against his foes has turned out to be far more expansive, creative, efficient — and less reliant on the justice system ...

Multiple sclerosis isn’t inherited, but having a family member with the disease can increase your chance of having the condition. While genetics influences your risk, environmental factors also ...

This article summarizes selected data from clinical trials of ozanimod ... treated with ozanimod is also ongoing. 6 Safety Patterns Over up to 8 Years with Ozanimod in Patients with Relapsing Multiple ...

Multiple sclerosis (MS) is a chronic, often disabling condition that ... then completed a residency in neurology and a combined clinical/research fellowship in movement disorders and ...

New findings reveal how a specific immune response to the Epstein-Barr virus could trigger multiple sclerosis ... study published in the Journal of Clinical Investigation, a group of researchers ...

Were you surprised by these results? What were the primary outcomes of the phase 2B study of tolebrutinib in relapsing multiple sclerosis? What was seen in the 3-year data? How do payers view the ...

2 As Bionews reported, prior research has not argued for a particular diet regimen in patients with multiple sclerosis ... patterns, rather than on single foods/nutrients, in chronic disease ...